...Other deals have seen Takeda build out its vaccines business, including the 2012 acquisition of LigoCyte Pharmaceuticals Inc....

...January. Sagent Advisors advised LigoCyte. Polsinelli Shugart was Takeda's legal advisor, while Cooley was LigoCyte's. LigoCyte Pharmaceuticals Inc....

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will acquire LigoCyte Pharmaceuticals Inc. (Bozeman, Mont.) for $60 million up front, plus...

...program. GlycoVaxyn AG's SD113 semisynthetic bioconjugate vaccine against Shigella dysenteriae has completed Phase I testing. LigoCyte Pharmaceuticals Inc....

...from GlaxoSmithKline and ChiSys intranasal delivery technology from Archimedes. Archimedes Pharma Ltd. , Reading, U.K. LigoCyte Pharmaceuticals Inc....

...28 days apart in 98 healthy volunteers. The vaccine uses an MPL adjuvant from GlaxoSmithKline. LigoCyte Pharmaceuticals Inc....

...from GlaxoSmithKline and ChiSys intranasal delivery technology from Archimedes. Archimedes Pharma Ltd. , Reading, U.K. LigoCyte Pharmaceuticals Inc....

...from GlaxoSmithKline and ChiSys intranasal delivery technology from Archimedes. Archimedes Pharma Ltd. , Reading, U.K. LigoCyte Pharmaceuticals Inc....

...from GlaxoSmithKline and ChiSys intranasal delivery technology from Archimedes. Archimedes Pharma Ltd. , Reading, U.K. LigoCyte Pharmaceuticals Inc....

...and a coauthor of the PNAS paper . Cutler is a founder of vaccine company LigoCyte Pharmaceuticals Inc....
...Institutions Mentioned Children's Hospital, New Orleans , New Orleans, La. GlycoVaxyn AG , Schlieren, Switzerland LigoCyte Pharmaceuticals Inc....